INVACO Acquires ENANTIA to Drive Expansion and Growth in Specialized CRO Services

Barcelona, January 29^th, 2025

Enantia, a leading contract research organization (CRO) with over 20 years of experience in chemistry services, has been fully acquired by INVACO, a company controlled by the venture capital fund Inveready Biotech IV, which specializes in life sciences and health. This strategic acquisition marks the beginning of an ambitious growth plan, including the integration of specialized small CROs to provide comprehensive R&D services.

The transaction includes the participation of Enantia’s management team as shareholders, reinforcing their commitment to the company’s future. The collaboration between Enantia and Inveready will facilitate expansion into new markets while executing a targeted acquisition strategy to consolidate a group of highly specialized CROs serving the pharmaceutical, biotech, and materials industries.

Operating from its facilities at the Parc Científic de Barcelona and Esplugues de Llobregat, Enantia has built a strong reputation in medicinal chemistry, chemical process development, and solid-state R&D. With a team of highly skilled professionals, the company provides high-quality research and development services to an international client base.

September 29th, 2023

Enantia attended the current edition of BIOSPAIN, the main national biotech event and one of the most important in Europe, attracting over 850 entities seeking collaboration opportunities in the field of drug development.

From September 26th to 28th, we engaged with the dynamic biotech community and explore ground-breaking opportunities for collaboration.

We discussed our services in Medicinal Chemistry (design and synthesis of focused libraries), Process Chemistry (such as route scouting and CMC support), Solid Form Screening and Development (optimizing candidate properties, improving IP and obtaining purification processes) and Solid Form Analysis (for a detailed understanding of the solid phase in the development and manufacturing of APIs and fine chemicals).

If you missed connecting with us at the event, discover how Enantia can support your project at info@enantia.com.

We’re committed to advancing innovation in drug discovery in the biotech and pharma industry!

July 4th and 5th, 2023

Enantia is attending this year’s edition of BOS Basel, taking place the 4th and 5th of July.

As a leading CRO in Process Chemistry, Solid Form Development and Medicinal Chemistry, we have been committed to meet our clients’ needs regarding the research and development of Small Organic Molecules, including Highly Potent APIs, since 2003. Our strengths as key providers of CMC services are:

• Optimizing, scaling-up and impurity profiling of routes of synthesis
• Purification technologies based on crystallizations and cocrystallizations
• Solid Form Development (being pioneers in the screening of cocrystals) and Solid Form Analysis

Find us through the partnering platform and at info@enantia.com. We will be glad to meet you to explore new synergies together.

See you in Basel!

January 25th, 2023

The French Ministry of Higher Education and Research has granted Enantia with the Crédit d’Impôt Recherche (CIR) (i.e., R&D tax credit) for a further three-year period: 2023, 2024 and 2025.

Thanks to the support of Crédit d’Impôt Recherche, French companies can incur research and development costs and be partially reimbursed for these expenses. The objective of this measure is to promote business innovation and competitiveness at national and international level.

We are glad to share this great news with our French customers, especially those with a strong R&D activity. This includes pharmaceutical companies, biotechs, CDMOs and CMOs, which can benefit from our CIR accreditation in all our services, such as medicinal chemistry, chemical development, solid state development and solid form analysis.

You can find our CIR accreditation here.